Literature DB >> 27224656

The Cycloaddition of the Benzimidazolium Ylides with Alkynes: New Mechanistic Insights.

Costel Moldoveanu1, Gheorghita Zbancioc1, Dorina Mantu1, Dan Maftei1, Ionel Mangalagiu1.   

Abstract

New insights concerning the reaction mechanism in the cycloaddition reaction of benzimidazolium ylides to activated alkynes are presented. The proposed pathway leading both to 2-(1H-pyrrol-1-yl)anilines and to pyrrolo[1,2-a]quinoxalin-4(5H)-ones involves an opening of the imidazole ring from the cycloaddition product, followed by a nucleophilic attack of the aminic nitrogen to a proximal carbonyl group and the elimination of a leaving group. The mechanistic considerations are fully supported by experimental data, including the XRD resolved structure of the key reaction intermediate.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27224656      PMCID: PMC4880325          DOI: 10.1371/journal.pone.0156129

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Pyrrolo[1,2-a]quinoxalinone derivatives are an important class of heterocyclic compounds due to their biological activities. Some carboxylic acid derivatives of pyrrolo[1,2-a]quinoxalin-4(5H)-one show significant (about 100 times larger than disodium cromoglycate) antiallergic activity in the passive cutaneous anaphylactic (PCA) test following either, and in some cases both, intravenous or oral dosing [1]. Moreover, the quinoxaline system has been identified as a critical structural requirement for optimal interaction with the human immunodeficiency virus type 1 (HIV-1) non-nucleoside reverse transcriptase inhibitors (NNRTI) binding site [2]. 6-Fluoro-quinoxalinylethylpyridylthiourea (6-FQXTP, Fig 1) represent the prototype of this class of NNRTI [2].
Fig 1

Structural formula of 6-FQXTP.

Few methods are available for the synthesis of the pyrrolo[1,2-a]quinoxalinone. One method requires expensive palladium catalyst for an intramolecular carbon-nitrogen bond formation [3]. Another method requires copper-catalyzed intramolecular N-arylation of the Ugi four component reaction product of aldehydes, 2-iodoaniline, 2-indole carboxylic acids, and isocyanides in one-pot procedure [4]. Cycloelimination of ammonia by anhydrous tin (II) chloride–hydrochloric acid reduction of the pyridazinoquinoxalinones [5], gives the same pyrrolo[1,2-a]quinoxalinone derivatives. The pyrrolo[1,2-a]quinoxalinone scaffold was also obtained by 1,3-dipolar cycloaddition of non-stabilized pyridinium methylides to dipolarophiles [6]. The non-stabilized pyridinium methylides were generated from N-(silylmethyl)pyridine analogs via 1,4-silatropy [6]. The N-substituted-1-(2-nitrophenyl)-1H-pyrrole-2-carboxamides undergo denitrocyclisation with NaH in DMF to the corresponding 5-alkyl(or aryl) pyrrolo[1,2-a]quinoxalin-4(5H)-ones [7]. A widely used, but also disputed method for the synthesis of the pyrrolo[1,2-a]quinoxalinone derivatives is the cycloaddition reaction of the benzimidazolium ylides to dipolarophyles [8-15]. Among the first uses, the works of Ogura [12] report the formation, along the pyrrolo[1,2-a]benzimidazoles, of either 2-propenylidene-benzimidazolines (in the case of benzimidazolium ylides derived from acetophenones), or 1-oxo-1,5(2H)-pyrido[1,2-a]benzimidazoles (when using benzimidazolium ylides derived from halogeno-esters). The authors explain the formation of both byproducts by the aromatization of the imidazole ring concomitant with the opening of pyrrole ring, while in the case of the latter the subsequent elimination of a methoxy group is required. A few decades later, Zhang and Huang [9,10] isolated a pyrrolo[1,2-a]quinoxaline instead of the expected pyrrolo[1,2-a]benzimidazoles, the mechanism proposed to explain the finding involving a concerted ring expansion, and hence no intermediates. Recent highlights [11,16,17] show that, depending on the substituents and/or the conditions employed, the reaction may be tuned toward the formation of either pyrrolo[1,2-a]benzimidazoles, pyrrolo[1,2-a]quinoxalin-4-ones [16] or pyrrolo[1,2-a]quinoxalines [11]. The mechanism proposed involves aromatization of the pyrrole ring concomitant with the opening of imidazole ring leading to 2-pyrrolo-aniline intermediates. Intermediates bearing good leaving groups in the 2nd position of the pyrrole ring allow further elimination to give pyrrolo[1,2-a]quinoxalin-4-ones, whereas a non-leaving group leads to pyrrolo[1,2-a]quinoxalines. However, no intermediate was isolated in any of the previous works. In view of the above consideration and our background in the cycloimmonium ylides area [18-29], we decided to investigate the cycloaddition reaction of the benzimidazolium ylides, with dimethylacetylene dicarboxylate (DMAD) as dipolarophile in order to elucidate the reaction mechanism.

Materials and Methods

Apparatus and analysis

All reagents and solvents were purchased from commercial sources and used without further purification. Melting points were recorded on a MEL-TEMP II apparatus in open capillary tubes and are uncorrected. Analytical thin-layer chromatography was performed with commercial silica gel plates 60 F254 (Merck) and visualized under UV light. The NMR spectra were recorded on a Bruker Avance III 500 MHz spectrometer operating at 500 MHz for 1H and 125 MHz for 13C. Infrared (IR) data were recorded as films on potassium bromide (KBr) pellets on a FT-IR Shimadzu Prestige 8400s spectrophotometer. The X-Ray diffraction experiment was performed using a SuperNova Dual diffractometer equipped with a Cu (Kα radiation, λ = 0.684 Å) fine-focus sealed X-ray tube and a graphite monochromator. Detector resolution: 16.1593 pixels mm-1. Absorption correction: multi-scan (CrysAlis PRO; Agilent, 2011), Tmin = 0.914, Tmax = 1.000. The reflections were recorded at room temperature on a small single crystal.

Typical procedure for the cycloaddition reaction of the benzimidazolium ylides with DMAD

A mixture of benzimidazolium salts 1a-i (3 mMol) and DMAD (0.852 g, 6 mMol) was suspended in 15 mL chloroform. Then, triethylamine (0.606 g, 6 mMol) dissolved in 10 mL chloroform was added drop wise under stirring in one hour. The stirring and refluxing were continued for 12 hours. After the reaction was finished (TLC), the obtained solution was cooled down at room temperature and then the reaction mixtures was washed with water (3 x 30 mL), dried over magnesium sulfate and evaporated under reduced pressure to give the crude product. The purification of the crude product was done by column chromatography on silica gel (eluted with CH2Cl2 to 98/2 CH2Cl2/ CH3OH) giving either two products in the cases of the 1a and 1b salts or a single product in the other cases.

Results and Discussion

The cycloaddition reaction of cycloimmonium ylides involves three stages: (i) generation of the ylide from the corresponding salt; (ii) a Huisgen 3+2 cycloaddition of ylide to dipolarophile, with the formation of a cycloadduct; (iii) total or partial dehydrogenation of the intermediary cycloadduct, with the final formation of a thermodynamically more stable aromatized adduct (Fig 2). The first two stages have been thoroughly investigated and described in literature [30,31], while the intermediate’s dehydrogenation in the third stage leads to a large variety of products including total or partial hydrogenated [21,23], fully aromatized cycloadducts [18-29] or even with an altered structure of the cycloadduct [8,9,12,14]. It is the latter case we focus in the following.
Fig 2

Reaction pathway for the cycloaddition of cycloimmonium salts to olefinic dipolarophiles.

In order to rationalize the literature data, to elucidate the reaction mechanism and to obtain new pyrrolo[1,2-a]quinoxalinone derivatives, we decide to study the reactions of benzimidazolium ylides (generated in situ, using triethylamine, from the corresponding salts 1a-i [27-29]) with the activated alkyne, DMAD, (Fig 3).
Fig 3

Reaction pathway for the cycloaddition reactions of benzimidazolium ylides to DMAD.

In contrast to literature data [12-14,16,17,19,21,26], in our case we did not isolate any hydrogenated (type a), partially hydrogenated (type b) or fully aromatized cycloadduct (type c), see Fig 2. Instead, in the case of ylides 2a,b, two types of stable products were obtained and isolated: 2-(1H-pyrrol-1-yl)anilines (4a and 4b), and pyrrolo[1,2-a]quinoxalin-4(5H)-one 5 (Fig 3, pathway ). In the case of the other ylides 2c-i only pyrrolo[1,2-a]quinoxalin-4(5H)-ones 5, 6 and 7 were isolated, whereas the NMR spectra of the crude products indicate the presence of the 2-(1H-pyrrol-1-yl)anilines 4c-i as unstable intermediates, which in time stabilize to quinoxaline derivatives 5, 6 and 7 (Fig 3, pathway ). XRD resolved structure of an isolated reaction intermediate (4b, Fig 4) suggests that after the initial formation of the cycloaddition products with a dihydropyrrolo[1,2-a]benzimidazole structure (3a-i), the reaction mechanism (Fig 5) involves a ring opening of the imidazole cycle [10,11,16,17] (and not of the pyrrole ring as proposed previously in the literature [12]) with the formation of a conformer of the 2-(1H-pyrrol-1-yl)anilines 4a-i.
Fig 4

ORTEP representation at 50% probability for compound 4b.

Fig 5

Proposed mechanism for the cycloaddition reactions of benzimidazolium ylides to DMAD.

The formation of compounds 4a,b may be assisted by the abstraction of the hydrogen atom from the acidic α-position of the ester/amide Y in the presence of excess triethylamine with concomitant fragmentation of the imidazole ring and aromatization of the pyrrole ring. Twisted conformations of the resulting 2-(1H-pyrrol-1-yl)anilines 4a-i (76° in the case of 4b) arise from a free rotation of the pyrrole ring around the Npyrrole-Caryl single bond. According to the nature of Z and Y substituents, the amines 4a-i are either stable (compounds 4a,b) or unstable (compounds 4c-i), a cyclization process to the six-membered ring of pyrrolo[1,2-a]quinoxalin-4(5H)-one structure (5–7) taking place in case of the latter, via elimination of an alkoxy group, Y (Fig 3, pathway ). Given the tendency of spontaneous cyclization observed in the case of amines 4c-i, our next attempt was to convert the amines 4a,b into a corresponding pyrrolo[1,2-a]quinoxalin-4(5H)-one structure, expected to be thermodynamically more stable. Indeed, the desired pyrrolo[1,2-a]quinoxalin-4(5H)-one 5 was easily obtained from both 4a and 4b cases by reflux in solution (Fig 3). Conversion of the two amines to the corresponding quinoxalinone also occurs at room temperature, in solution. Results of 1H NMR studies on 4b at room temperature (see S6 Fig) reveal that intramolecular cyclization is a slow process, spectra recorded after 11 days from sample preparation containing signals from both 4b and 5 in nearly equimolar ratio. The isolation of the 2-(1H-pyrrol-1-yl)anilines 4a,b is the missing link that confirms the mechanism proposed by Georgescu [11,16,17] and in the same time infirms the concerted mechanism proposed by Zhang and Huang [9,10]. A summary of the products yielded through the cycloaddition of the benzimidazolium ylides to DMAD are listed in Table 1.
Table 1

Yields and products obtained in the cycloaddition reactions of benzimidazolium ylides 2a-i.

SaltZXY2-(1H-pyrrol-1-yl)anilinesYield (%)pyrrolo[1,2-a]quinoxalin-4(5H)-onesYield (%)
2aCNBrOMe4a19519
2bCNBrOEt4b19512
2cCNINH24c-a510
2dCO2MeBrOMe4d-a639
2eCO2MeBrOEt4e-a623
2fCO2MeINH24f-a615
2gCO2EtBrOMe4g-a726
2hCO2EtBrOEt4h-a726
2iCO2EtINH24i-a710

Yields given in lines 1 and 2 are additive (it was a mixture of 4 + 5 with the individual yields of the two components given after their column chromatography separation from the product mixture ΔRf = 0.15 on 97/3 CH2Cl2/ CH3OH)

aNot isolated, observed in NMR of the crude reaction mixture. Reaction conditions: benzimidazolium salts: DMAD: triethylamine = 1:2:2; then refluxing for 12 hours in chloroform

Yields given in lines 1 and 2 are additive (it was a mixture of 4 + 5 with the individual yields of the two components given after their column chromatography separation from the product mixture ΔRf = 0.15 on 97/3 CH2Cl2/ CH3OH) aNot isolated, observed in NMR of the crude reaction mixture. Reaction conditions: benzimidazolium salts: DMAD: triethylamine = 1:2:2; then refluxing for 12 hours in chloroform One may note from Table 1 that the isolated yields are low to moderate, in good agreement with values reported in the literature for this type of reactions. The lower yields in the case of the benzimidazolium ylides 2c, 2f and 2i should relate to a different behaviour of the NH2 as leaving group compared to the alkoxy counterpart, that impacts in case of the former on cyclization to quinoxaline ring. The structures of cycloaddition products 4a-i, 5, 6, 7 were determined unambiguously by spectral analysis (IR, 1H-NMR, 13C NMR, and two-dimensional experiments 2D-COSY, 2D-HETCOR (HMQC), long range 2D-HETCOR (HMBC) and finally, in the case of 2-(1H-pyrrol-1-yl)anilines 4b, and pyrrolo[1,2-a]quinoxalin-4(5H)-one 6 also by single crystal X-ray diffraction (Figs 4 and 6 respectively).
Fig 6

ORTEP representation at 50% probability for compound 6.

Conclusions

Our results reported herein complement previously reported literature data regarding the cycloaddition of benzimidazolium ylides to dipolarophiles, adding new insights into the reaction mechanism. A plausible explanation for obtaining both types of cycloaddition products is provided by the reaction mechanism and correlates to the literature data. The proposed pathway leading both to 2-(1H-pyrrol-1-yl)anilines and to pyrrolo[1,2-a]quinoxalin-4(5H)-ones, involving the opening of the imidazole ring, is supported by spectral analysis and X-ray diffraction experiments. We also shown that reaction selectivity toward pyrrolo[1,2-a]quinoxalin-4(5H)-ones may be tuned by experimental conditions.

Crystallographic Information Files (CIF) of the compound 4b.

(CIF) Click here for additional data file.

Crystallographic Information Files (CIF) of the compound 6.

(CIF) Click here for additional data file. (a) 1H NMR spectrum of the compound 4a.(b) 13C NMR spectrum of the compound 4a. (TIF) Click here for additional data file. (a) 1H NMR spectrum of the compound 4b.(b) 13C NMR spectrum of the compound 4b. (TIF) Click here for additional data file. (a) 1H NMR spectrum of the compound 5.(b) 13C NMR spectrum of the compound 5.(c) Detail on 13C NMR spectrum of the compound 5. (TIF) Click here for additional data file. (a) 1H NMR spectrum of the compound 6.(b) 13C NMR spectrum of the compound 6. (TIF) Click here for additional data file. (a) 1H NMR spectrum of the compound 7.(b) 13C NMR spectrum of the compound 7. (TIF) Click here for additional data file.

Time evolution of the 1H-NMR spectrum of 2-ethyl 3,4-dimethyl 1-(2-(2-cyanoethylamino)phenyl)-1H-pyrrole-2,3,4-tricarboxylate (4b).

(TIFF) Click here for additional data file.

Supporting Information document.

Spectral characterization, NMR spectra (1H and 13C) of the obtained compounds, and 1H-NMR studies on 4b at room temperature. (DOCX) Click here for additional data file.
  6 in total

1.  Ultrasound assisted reactions of steroid analogous of anticipated biological activities.

Authors:  Vasilichia Bejan; Costel Moldoveanu; Ionel I Mangalagiu
Journal:  Ultrason Sonochem       Date:  2008-11-05       Impact factor: 7.491

2.  Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent.

Authors:  G Campiani; F Aiello; M Fabbrini; E Morelli; A Ramunno; S Armaroli; V Nacci; A Garofalo; G Greco; E Novellino; G Maga; S Spadari; A Bergamini; L Ventura; B Bongiovanni; M Capozzi; F Bolacchi; S Marini; M Coletta; G Guiso; S Caccia
Journal:  J Med Chem       Date:  2001-02-01       Impact factor: 7.446

3.  Ultrasound assisted synthesis of imidazolium salts: an efficient way to ionic liquids.

Authors:  Gheorghita Zbancioc; Ionel I Mangalagiu; Costel Moldoveanu
Journal:  Ultrason Sonochem       Date:  2014-11-03       Impact factor: 7.491

4.  Synthesis and oral antiallergic activity of carboxylic acids derived from imidazo[2,1-c][1,4]benzoxazines, imidazo[1,2-a]quinolines, imidazo[1,2-a]quinoxalines, imidazo[1,2-a]quinoxalinones, pyrrolo[1,2-a]quinoxalinones, pyrrolo[2,3-a]quinoxalinones, and imidazo[2,1-b]benzothiazoles.

Authors:  I R Ager; A C Barnes; G W Danswan; P W Hairsine; D P Kay; P D Kennewell; S S Matharu; P Miller; P Robson; D A Rowlands
Journal:  J Med Chem       Date:  1988-06       Impact factor: 7.446

5.  New highlights of the syntheses of pyrrolo[1,2-a]quinoxalin-4-ones.

Authors:  Emilian Georgescu; Alina Nicolescu; Florentina Georgescu; Florina Teodorescu; Daniela Marinescu; Ana-Maria Macsim; Calin Deleanu
Journal:  Beilstein J Org Chem       Date:  2014-10-14       Impact factor: 2.883

6.  Microwave assisted reactions of some azaheterocylic compounds.

Authors:  Gheorghita Zbancioc; Vasilichia Bejan; Marian Risca; Costel Moldoveanu; Ionel I Mangalagiu
Journal:  Molecules       Date:  2009-01-15       Impact factor: 4.411

  6 in total
  3 in total

1.  Ultrasound-Assisted Synthesis of Fluorescent Azatetracyclic Derivatives: An Energy-Efficient Approach.

Authors:  Gheorghita Zbancioc; Catalina-Ionica Ciobanu; Ionel I Mangalagiu; Costel Moldoveanu
Journal:  Molecules       Date:  2022-05-16       Impact factor: 4.927

2.  Ultrasound assisted synthesis of hybrid quinoline-imidazole derivatives: a green synthetic approach.

Authors:  Dumitrela Diaconu; Dorina Amăriucăi-Mantu; Violeta Mangalagiu; Vasilichia Antoci; Gheorghita Zbancioc; Ionel I Mangalagiu
Journal:  RSC Adv       Date:  2021-11-29       Impact factor: 3.361

3.  New Pyrrole Derivatives as Promising Biological Agents: Design, Synthesis, Characterization, In Silico, and Cytotoxicity Evaluation.

Authors:  Beatrice-Cristina Ivan; Stefania-Felicia Barbuceanu; Camelia Mia Hotnog; Adriana Iuliana Anghel; Robert Viorel Ancuceanu; Mirela Antonela Mihaila; Lorelei Irina Brasoveanu; Sergiu Shova; Constantin Draghici; Octavian Tudorel Olaru; George Mihai Nitulescu; Mihaela Dinu; Florea Dumitrascu
Journal:  Int J Mol Sci       Date:  2022-08-09       Impact factor: 6.208

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.